symdeko approv guidanc
new target price higher price
tezacaftor/ivacaftor known symdeko approv
fda today line expect pdufa drug
februari think time earli approv broadli
anticip compani also releas revenu guidanc
guid total cystic fibrosi revenu line
consensu updat cs estim think
expect compani might give conserv guidanc midst
symdeko price higher forecast rais
cf sale target price announc
price symdeko vs forecast price
orkambi price compani say primarili
target orkambi discontinu symdeko check suggest
physician may inclin switch mani orkambi
patient didnt see strong respons given higher price
symdeko vertex top-line like benefit switch happen
although payer reimburs gate factor cours
risk outperform rate target price includ clinic
setback tripl combin greater expect competit
commerci cf space ep higher vs previous
rais revenu due higher expect symdeko price
specif ep vs previous
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
vertex biotechnolog compani research develop
commerci small molecul drug focu cystic
fibrosi product kalydeco orkambi
price feb rate outperform target price analyst alethia young
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky scenario use dcf valu
share cut sg respect
grey sky scenario model less credit triplet
lower probabl success reflect increas risk
compani face meaning setback
forecast symdeko revenu switch rate
orkambi big swing factor estim patient age
us discontinu orkambi forecast vast major
initi symdeko end model sale orkambi
vs sale kalydeco vs
think vertex solid execut set catalyst lead
outperform market key investor debat major
catalyst play howev think could get top-line phase triplet
data could major valu driver stock note also glpg
data mid-year tripl think vertex set high efficaci
hurdl cautiou aggress glpg timelin beyond
compani top bottom line growth think attent turn
new program may leverag protein fold platform alreadi exist
cf reiter outperform top pick within larg small/mid cap coverag
compani mention price
